| 08:00 |
Welcome and Introductions
Christine Chen
|
| 08:10 |
Challenges of Getting a Lymphoma Patient to CAR T
Jeremy Abramson, Director of Centre for Lymphoma, Massachusetts General Hospital (MGH), Boston
|
| 08:50 |
CAR T in Myeloma: What Have We Learned?
Tom Martin University of California San Francisco (UCSF) Associate Director Myeloma Program
|
| 09:30 |
CAR T-Cell Therapy for Autoimmune Disease
Zahi Touma, UHN Head of Lupus Program
|
| 10:00 |
Break
|
| 10:30-11:20 |
Small Group Session A
Small group sessions are fully interactive between faculty and participants. For planning purposes, pre-registration for workshops is required. Participants are encouraged to bring cases and questions for discussion.
|
|
1) CAR T in Lymphoma
A.Prica, J.Kuruvilla, I.Gong
|
|
2) CAR T in ALL
H.Sibai, M.Perusini, D.Eng
|
|
3) CAR T in Myeloma
T.Martin, S.Bhella, R.Latscha
|
|
4) Longterm Follow-up Post-CAR T
J. Abramson, C.Chen, A.Alshami
|
| 11:30-12:20 |
Small Group Session B
Small group sessions are fully interactive between faculty and participants. For planning purposes, pre-registration for workshops is required. Participants are encouraged to bring cases and questions for discussion.
|
|
1) CAR T in Lymphoma
A.Prica, J. Kuruvilla, I.Gong
|
|
2) CAR T in ALL
H.Sibai, M.Perusini, D.Eng
|
|
3) CAR T in Myeloma
T.Martin, Drs. S.Bhella, R.Latscha
|
|
4) Longterm Follow-up Post-CAR T
J. Abramson, C.Chen, A.Alshami
|
| 12:20 |
Lunch break
Lunch break
|
| 01:00 |
Infections in CAR T 101
Victoria Hall, UHN Oncology Infectious Diseases
|
| 01:30 |
Tumor Infiltrating Lymphocytes (TILS) in Solid Tumor
Marcus Butler, PM Tumor Immunotherapy Program
|
| 02:00 |
Sequencing – CAR T vs Bispecifics in Lymphoma
John Kuruvilla, PM Lymphoma Site Lead
|
| 02:30 |
Closing Remarks
Christine Chen
|
